Loading...
In the Standard and New Antiepileptic Drug (SANAD) trial (JW Gen Med Apr 10 2007), 1721 patients with suspected focal epilepsy were randomized equally to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate, to compare outcomes with the newer medications versus the older medication (carbamazepine). Now, researchers have conducted a post hoc analysis of the data to determine clinical factors that affect the probabilities of treatment failure and of achieving 12-month remission. Time to treatment failure was divided into failure caused by inadequate seizure control or by unacceptable adverse effects.
As was previously reported, compared with carbamazepine, the overall risk for treatment failure was significantly lower with lamo…